170 related articles for article (PubMed ID: 29648921)
1. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: ASCO Clinical Practice Guideline Summary.
Morris MJ; Rumble RB; Milowsky MI
J Oncol Pract; 2018 May; 14(5):319-322. PubMed ID: 29648921
[No Abstract] [Full Text] [Related]
2. Chemotherapy for metastatic castrate-sensitive prostate cancer.
Miller RE; Sweeney CJ
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
[TBL] [Abstract][Full Text] [Related]
3. Bipolar androgen therapy in the treatment of prostate cancer.
Denmeade SR
Clin Adv Hematol Oncol; 2018 Jun; 16(6):408-411. PubMed ID: 30067610
[No Abstract] [Full Text] [Related]
4. Treatment of castrate-resistant prostate cancer.
Logothetis CJ
J Urol; 2013 Aug; 190(2):439-40. PubMed ID: 23707438
[No Abstract] [Full Text] [Related]
5. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
6. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Shore ND
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):17-9. PubMed ID: 27167847
[No Abstract] [Full Text] [Related]
7. CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.
Teo MY; Scher HI
Nat Rev Clin Oncol; 2015 Dec; 12(12):687-8. PubMed ID: 26552950
[No Abstract] [Full Text] [Related]
8. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Sweeney CJ
Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
[No Abstract] [Full Text] [Related]
9. Metastatic castrate-resistant prostate cancer, dawn of a new age of management.
Nemr EG
BJU Int; 2013 Mar; 111(3):E9-E10. PubMed ID: 23444940
[No Abstract] [Full Text] [Related]
10. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
11. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
Martorana G
Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
[No Abstract] [Full Text] [Related]
13. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
14. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.
Denis L; Murphy GP
Cancer; 1993 Dec; 72(12 Suppl):3888-95. PubMed ID: 8252511
[No Abstract] [Full Text] [Related]
15. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
16. First-line use of novel hormonal agents in prostate cancer: a critical appraisal.
Raghavan D
Clin Adv Hematol Oncol; 2018 Apr; 16(4):289-295. PubMed ID: 29742084
[TBL] [Abstract][Full Text] [Related]
17. Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Taneja SS
J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209521
[No Abstract] [Full Text] [Related]
18. Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.
Thompson AL; Sarmah P; Beresford MJ; Jefferies ER
BJU Int; 2017 Dec; 120(6):751-754. PubMed ID: 28834013
[No Abstract] [Full Text] [Related]
19. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
